BR01T / Brise Pharma - LARVOL DELTA

Brise Pharma Announces First Patient Dosed with BR01T in Phase I Study in Patients with Chronic Low Back Pain (PRNewswire) - "Brise Pharmaceuticals Co., LTD...has taken a significant step forward with the commencement of dosing for the initial participants in its Phase 1 clinical trial, designated MBR01T-101. The trial focuses on the safety and tolerability study of BR01T, a groundbreaking monoclonal antibody designed to target Tropomyosin Receptor Kinase (TrkA) for addressing Chronic Low Back Pain (CLBP)."

Trial status • Back Pain • CNS Disorders • Lumbar Back Pain • Musculoskeletal Pain • Pain